Discovery of a pituitary adenoma following treatment with a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
We report the case of a T3 prostate cancer in a 70-year-old white man. Hormone therapy represents a prominent branch in the treatment of locally advanced and metastatic prostate cancer. Gonadotropin-releasing hormone agonists have been proven to have a double effect on androgen metabolism: an initially stimulating, followed by an inhibitory, effect on the pituitary gland. This phenomenon may be noxious in the case of gonadotroph adenoma, with subsequent symptoms of intracranial hypertension. Gonadotropin-releasing hormone antagonists (abarelix), by avoiding the flare-up reaction, might be used in such instances.
Massoud
Walid
W
Department of Urology, Lyon-Sud Hospital, Lyon, France.
Paparel
Philippe
P
Lopez
Jean-Gabriel
JG
Perrin
Paul
P
Daumont
Michele
M
Ruffion
Alain
A
D000230:Adenocarcinoma / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D000236:Adenoma / Q000139:chemically induced* / Q000175:diagnosis; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects* / Q000627:therapeutic use; D001706:Biopsy; D003937:Diagnosis, Differential; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D016729:Leuprolide / Q000009:adverse effects* / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D008297:Male; D010911:Pituitary Neoplasms / Q000139:chemically induced* / Q000175:diagnosis; D011471:Prostatic Neoplasms / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D014057:Tomography, X-Ray Computed
D018931:Antineoplastic Agents, Hormonal; D007987:Gonadotropin-Releasing Hormone; D016729:Leuprolide